University of Florida
ufl.eduTotal trials
1,263
Active
254
Phase 3
26
Total enrollment
384,080
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 87 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Clopidogrel | — | — | — | — | — | 8 | |
| Aspirin plus clopidogrel | — | — | — | — | — | 2 | |
| Ropivacaine | — | — | — | 5 | |||
| Cangrelor | — | — | — | — | — | 4 | |
| Clopidogrel 75 mg | — | — | — | — | — | 2 | |
| Fluoxetine | — | — | — | — | 2 | ||
| Ticagrelor 60mg | — | — | — | — | — | 2 | |
| High dose potent statin | — | — | — | — | — | 1 | |
| ACE-I | — | — | — | — | — | 1 | |
| Aspirin 81 enteric coated tablet daily | — | — | — | — | — | 1 | |
| Lasix ONYU | — | — | — | — | — | 1 | |
| PrEP acronym | — | — | — | — | — | 1 | |
| Ticagrelor 90 mg | — | — | — | — | — | 1 | |
| Prasugrel 10 mg | — | — | — | — | — | 1 | |
| TIVA | — | — | — | — | — | 1 | |
| Balanced anesthesia | — | — | — | — | — | 1 | |
| Minocycline Hydrochloride | — | — | — | — | — | 1 | |
| Prasugrel 5 mg | — | — | — | — | — | 1 | |
| Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel | — | — | — | — | — | 1 | |
| prasugrel or ticagrelor | — | — | — | — | — | 1 | |
| Prasugrel | — | — | — | — | 10 | ||
| Tadalafil | — | — | — | — | 2 | ||
| Pfizer-BioNTech mRNA COVID-19 vaccine | — | — | — | — | — | 1 | |
| Ticagrelor + Aspirin | — | — | — | — | — | 1 | |
| Rivaroxaban + Aspirin | — | — | — | — | — | 1 | |
| Clopidogrel + Aspirin | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | 4 | ||
| AB-free kava | — | — | — | — | 2 | ||
| Cisplatin | — | — | — | — | 3 | ||
| Methylphenidate Pill | — | — | — | — | 2 | ||
| Temozolomide | — | — | — | — | — | 2 | |
| Kava | — | — | — | — | 2 | ||
| Epidiferphane | — | — | — | — | — | 2 | |
| Taxane Chemotherapy | — | — | — | — | — | 2 | |
| Gemcitabine | — | — | — | — | — | 2 | |
| Indocyanine green | — | — | — | — | — | 2 | |
| Metformin | — | — | — | — | — | 1 | |
| Genotype | — | — | — | — | — | 1 | |
| pp65 RNA LP | — | — | — | — | — | 1 | |
| Intermediate-dose ivermectin | — | — | — | — | — | 1 |
47 more active programs hidden
Next readouts
- 2022-11-26
- 2023-09-16
- 2024-08-26
- 2025-02-14
- 2025-09-05
- 2025-12
- 2025-12-01
- 2025-12-31
- 2026-01-23
- 2026-01-26
Top conditions
- Healthy48
- Coronary Artery Disease35
- Aging33
- Obesity27
- Hypertension23
- Parkinson Disease21
- Pain20
- Breast Cancer19
Frequently asked questions about University of Florida
- How many clinical trials does University of Florida have on ClinicalTrials.gov?
- University of Florida is listed as the lead sponsor on 1,263 clinical trials in ClinicalTrials.gov, 254 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Florida's trials are in Phase 3?
- 26 of University of Florida's trials are in Phase 3, spread across 87 active drug programs.
- What therapeutic areas does University of Florida focus on?
- University of Florida's most-studied conditions on ClinicalTrials.gov are Healthy, Coronary Artery Disease, Aging, Obesity, Hypertension.
- When are University of Florida's next clinical trial readouts?
- University of Florida has 10 upcoming primary-completion readouts tracked here; the soonest is “Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)”, expected around 2022-11-26.